MedPath

Kozhnosys developed by the CanScan prototype is being utilized in an observational study to collect and analyze volatile markers in the exhaled breath of cancer (GI, Cervical, Colorectal, head and neck) patients.

Not Applicable
Conditions
Health Condition 1: R978- Other abnormal tumor markers
Registration Number
CTRI/2024/03/063799
Lead Sponsor
Kozhnosys Private Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Inclusion Criteria for GI, Cervical, Colorectal, head, and neck Cancer

1. Willing to fill out the informed consent form

2. Female in the age group 20 to 80 years Women with newly diagnosed cancer (GI, Cervical, Colorectal, head, and neck) with/without common medical conditions like Hypertension, Hyperlipidaemia, Hypothyroidism, Arthritis, Asthma, GERD, Diabetes, PCOD, Vitamin deficiencies, etc. -20 evaluable subjects (4 patients each with above-mentioned cancer)

3. Confirmed cases of GI, Cervical, Colorectal, head, and neck cancer but not exposed to any previous treatment cycle/surgery.

4. Cases confirmed through endoscopy, PAP smear, Colonoscopy, MRI/CT, Ultrasonography or blood tests.

Exclusion Criteria

Exclusion Criteria for GI, Cervical, Colorectal, head, and neck cancer

1. The age group is below 20 years.

2. Any known illness within 2 weeks from breath collection.

3. Already undergoing cancer treatment.

4. Undergone surgery for cancer tumor removal.

5. Undergoing chemo/radiation therapy for cancer treatment.

6. Positive, but no GI, Cervical, Colorectal, head, and neck cancer on the later investigation (Positive Sonography but negative biopsy report).

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
VOC (Volatile organic compounds) profile in GI, colorectal, cervical, Head & neck cancers.Timepoint: 4 weeks
Secondary Outcome Measures
NameTimeMethod
Detection of volatile markers of biomarkers in GI, Colorectal, Cervical, Head, and Neck cancers using Canscan prototype. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: 4 weeks
© Copyright 2025. All Rights Reserved by MedPath